DBV Technologies SA (DBV) Stock Price & News - Google Finance

Finance

HomeDBV • EPA

DBV Technologies SA

€1.62

Sep 12, 6:00:00 PM GMT+2 · EUR · EPA · Disclaimer

Invesco DB Agriculture Fund

$27.50

DBA0.33%

Invesco DB US Dollar Index Bearish Fund

$18.83

UDN0.080%

Invesco DB US Dollar Index Bullish Fund

$27.39

UUP0.15%

Invesco DB Precious Metals Fund

$83.61

DBP0.54%

Invesco DB Commodity Index Tracking Fund

$22.35

DBC0.59%

DB Energy SA

zł 11.30

DBE1.74%

Invesco DB Oil Fund

$13.40

DBO0.83%

Invesco DB Base Metals Fund

$20.39

DBB0.84%

Nanobiotix SA

€8.37

NANO1.65%

Abionyx Pharma SA

€3.95

ABNX2.46%

StockFR listed security

Previous close

€1.64

Day range

€1.60 - €1.66

Year range

€0.51 - €2.38

Market cap

234.25M EUR

Avg Volume

395.46K

P/E ratio

-

Dividend yield

-

Primary exchange

EPA

Market news

Silicom Ltd.'s (NASDAQ:SILC) top owners are retail investors with 54% stake, while 41% is held by institutions

US Markets Wrap – All Indexes Finish the Week Higher

Assessing the Valuation of Vanguard S&P 500 ETF (VOO) as Investor Interest Quietly Builds

S&P 500 and Nasdaq hit records, traders look to Fed meeting

S&P 500 fights for another record — plus, Eaton signals big data center opportunity

Nasdaq Fires Employee Over Social Media Post on Kirk Shooting

About

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia

Founded

Mar 29, 2002

Website

dbv-technologies.com

Employees

109

Search

Clear search

Close search

Google apps

Main menu